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Queen Elizabeth Hospital Birmingham, Birmingham, United KingdomBackground & Aims: Hepatitis C virus (HCV) causes progressive Conclusions: These data provide new insights into the cancer-
liver disease and is a major risk factor for the development of
hepatocellular carcinoma (HCC). However, the role of infection
in HCC pathogenesis is poorly understood. We investigated the
effect(s) of HCV infection and viral glycoprotein expression on
hepatoma biology to gain insights into the development of HCV
associated HCC.
Methods:We assessed the effect(s) of HCV and viral glycoprotein
expression on hepatoma polarity, migration and invasion.
Results:HCV glycoproteins perturb tight and adherens junction
protein expression, and increase hepatomamigration and expres-
sion of epithelial to mesenchymal transition markers Snail and
Twist via stabilizing hypoxia inducible factor-1a (HIF-1a). HIF-
1a regulates many genes involved in tumor growth and metasta-
sis, including vascular endothelial growth factor (VEGF) and
transforming growth factor-beta (TGF-b). Neutralization of both
growth factors shows different roles for VEGF and TGFb in regu-
lating hepatoma polarity and migration, respectively. Impor-
tantly, we conﬁrmed these observations in virus infected
hepatoma and primary human hepatocytes. Inhibition of HIF-
1a reversed the effect(s) of infection and glycoprotein expression
on hepatoma permeability and migration and signiﬁcantly
reduced HCV replication, demonstrating a dual role for HIF-1a
in the cellular processes that are deregulated in many human
cancers and in the viral life cycle.Journal of Hepatology 20
Keywords: Hepatitis C; Hypoxia; Invasion.
Received 31 August 2011; received in revised form 25 October 2011; accepted 14
November 2011; available online 16 December 2011
⇑ Corresponding author. Address: Institute for Biomedical Research, University of
Birmingham, Birmingham B15 2TT, United Kingdom. Fax: +44 121 414 3599.
E-mail address: j.a.mckeating@bham.ac.uk (J.A. McKeating).
 Joint shared senior authorship.
Abbreviations: BC, bile canaliculi; CMFDA, 5-chloromethylﬂuorescein diacetate;
HCC, hepatocellular carcinoma; EMT, epithelial to mesenchymal transition; HC-
Vcc, hepatitis C virus cell culture; HIF-1a, hypoxia inducible factor 1 alpha; JFH-1,
Japanese fulminant hepatitis-1; MRP-2, multidrug resistant protein-2; PHH, pri-
mary human hepatocytes; SR-BI, scavenger receptor class B member 1; TGFb,
transforming growth factor-beta; TNFa, tumor necrosis factor alpha; VEGF, vas-
cular endothelial growth factor; VSV-G, vesicular stomatitis virus glycoprotein.promoting effects of HCV infection on HCC migration and offer
new approaches for treatment.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the most common liver malig-
nancy and rates ﬁfth in incidence and third in mortality in the
world [1,2]. HCC is a complex and heterogeneous tumor with fre-
quent intrahepatic spread and extrahepatic metastasis, resulting
in poor prognosis [3]. Our current understanding of the molecular
mechanisms underlying HCC pathogenesis is limited and further
studies are required to aid the design of strategies for HCC
treatment.
Hepatitis C virus (HCV) induces chronic liver injury that can
lead to progressive ﬁbrosis and is one of the leading causes of
HCC [4]. HCV is a positive stranded RNA ﬂavivirus that infects
hepatocytes and replicates in the cytoplasm without integration
into the host genome. The role of HCV infection in the carcino-
genic process is unclear, in part due to the limited availability
of small animal models that support HCV replication and techni-
cal difﬁculties in detecting HCV infected cells in the human liver
[5]. Reports, demonstrating that HCV encoded proteins interact
with cell cycle regulators and tumor suppressors, along with
the development of HCC in some HCV transgenic lineages, sug-
gest that HCV proteins may be directly oncogenic (reviewed in
[6]). HCV-associated HCC has been reported to be associated with
an increased recurrence after liver resection [7], suggesting that
HCV may promote tumor growth and metastasis.
Recent advances allowing the assembly of infectious HCV par-
ticles in vitro have enabled the complete virus lifecycle to be
studied [8]. HCV encodes two glycoproteins E1 and E2 that medi-
ate virus attachment to the host cell receptors: tetraspanin CD81
and scavenger receptor class BI (SR-BI). More recently, tight junc-
tion proteins Claudin-1 and Occludin have been implicated in12 vol. 56 j 803–809
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HCV entry (reviewed in [9]). We previously reported that HCV
infection reduced hepatoma polarity reminiscent of epithelial to
mesenchymal transition (EMT) [10]. Given the many reports
detailing aberrant tight junction protein expression and EMT in
malignant neoplasms including HCC [11–13] and the knowledge
that viruses frequently down regulate expression of their cellular
receptors, we investigated the effect(s) of HCV infection on
hepatoma migration and invasion. We demonstrate that HCV gly-
coproteins and virus infection reduce tight junction integrity and
E-Cadherin expression, promote EMT markers Snail and Twist
expression and hepatoma migration via stabilizing hypoxia
inducible factor 1a (HIF-1a), a transcriptional regulator that acti-
vates vascular endothelial growth factor (VEGF) and transforming
growth factor (TGFb) expression. We demonstrate a role for VEGF
and TGFb in de-regulating hepatoma polarity and promoting the
migration of infected cells. Inhibition of HIF-1a reversed the
effect(s) of virus glycoproteins and infection on hepatoma migra-
tion and signiﬁcantly reduced HCV replication, demonstrating a
dual role for HIF-1a in deregulating cellular processes associated
with tumor growth and in the viral life cycle. HIF-1a is expressed
in many human cancers and is considered a therapeutic target for
treating malignant diseases of diverse aetiologies. These data pro-
vide new insights into the role for HCV in HCC pathogenesis and
suggest new approaches for treatment.Materials and methods
Cell lines, antibodies and cytokine assays
HepG2 and Huh-7.5 were propagated in Dulbecco’s Modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino
acids. HepG2 cells were transduced to express human CD81, as previously
reported [14]. Human hepatocytes were isolated according to previously pub-
lished protocols [15] and maintained in Williams E medium supplemented with
10% FBS/5 mM HEPES/insulin/dexamethasone.
The following antibodies were used: anti-multi-drug resistant protein-2
(MRP-2), anti-vesicular stomatitis virus glycoprotein (VSV G) (Abcam), anti-
NS5A 9E10, anti-CD81 2s131, anti-SR-BI (BD Biosciences), anti-Occludin and
Claudin-1 (Invitrogen), anti-HIF-1a (Novus Biologicals), anti-VEGF VG76e, and
anti-HCV E2 3/11 [16]. Alexa-conjugated secondary antibodies were purchased
from Invitrogen. HIF-1a inhibitors NSC-134574 (NSC) and RITA were previously
reported [17,18]. Human VEGF and TGFb were measured by ELISA (Peprotech,
UK) according to the manufacturer’s instructions.
Expression of HCV and VSV glycoproteins
HepG2-CD81 cells were transfected with 4 lg of pcDNA3.1 plasmid encoding
HCV strain H77 E1E2 (genotype 1), JFH-1 E1E2 (genotype 2) or VSV-G using mag-
net assisted transfection (Fisher Scientiﬁc, UK). Plasmids encode H77 or JFH-1
amino acids 171–747, spanning the leader sequence of E1 and the entire E1E2
coding region (VBRC HCV database numbering system). Seventy-two hours post
transfection, the medium was replaced with 3% FBS/G418 (1 mg/ml) and glyco-
protein expression conﬁrmed by ﬂow cytometry.
Quantiﬁcation of hepatoma polarity and tight junction integrity
Parental, HCV glycoprotein and VSV-G-expressing cells were grown for 5 days in
culture to polarize before ﬁxation with paraformaldehyde. Cells were permeabi-
lized with PBS/0.5% BSA/0.1% Triton and stained for the apical marker MRP-2.
Nuclei were visualized with 40 ,60diamidino-2-phenylindole (DAPI) and polarity
index determined as the number of MRP-2 positive bile canalicular (BC) struc-
tures per 100 nuclei in 5-ﬁelds of view [19]. To assess tight junction integrity,
polarized cells were incubated with 5 mmol/L 5-chromomethylﬂuorescein diace-
tate (CMFDA) at 37 C for 15 min to allow translocation to BC. Following extensive
washing in PBS, the ability of BC to retain CMFDA was measured as an indicator of
tight junction integrity.804 Journal of Hepatology 201Confocal microscopy
Cells were grown on 13 mm borosilicate coverslips, methanol ﬁxed and perme-
abilized for 20 min in PBS/0.5% BSA/0.05% saponin. Cells were incubated with pri-
mary antibodies speciﬁc for Claudin-1, Occludin, HIF-1a, Snail, Twist or NS5A
(1 lg/ml) for 1 h. After a saponin/BSA/PBS wash, cells were incubated with
Alexa-conjugated secondary antibodies for 30 min. Cells were counterstained
with DAPI and mounted onto glass slides using ProLong Gold antifade (Invitro-
gen). Laser scanning confocal microscopy was performed using a Zeiss Metahead
confocal microscope with a 63 water objective.
Human tissue and immunohistochemistry
Formalin-ﬁxed parafﬁn embedded specimens were obtained from patients with
early and late stage liver disease, diagnosed according to the severity of ﬁbrosis,
where early = no/mild ﬁbrosis (Ishak stage <2) and late = cirrhosis. Normal tissue
was obtained from surplus donor tissue used for reduced-size liver transplanta-
tion. Informed consent was obtained together with regional ethics committee
approval. Immunohistochemical techniques were previously reported [20].
Microscopic examinations were performed by two independent observers. Occlu-
din distribution was quantiﬁed on a scale of 0–3 according to its location at apical
or basolateral membranes. The distribution in 5-ﬁelds of view from ﬁve cases for
each disease was scored, deﬁned as the percentage of hepatocytes expressing
Occludin at apical or basolateral membranes, where 0 = <5%, 1 = 5–33%, 2 = 33–
66% and 3 = >66%.
HCV infection
HCV J6/JFH-1 virus was generated as previously described [21]. Cells were
infected for 72 h under hypoxic (1% O2) or normoxic (20% O2) conditions in the
presence or absence of HIF-1a inhibitor NSC (1 lM), previously shown to have
a minimal effect on cell proliferation. Infected cells were detected by methanol-
ﬁxation and staining for HCV NS5A with mAb 9E10 and Alexa-594 anti-mouse.
HCV RNA was quantiﬁed by RT-PCR following manufacturer’s guidelines (Invitro-
gen) using an MxPro 3000 real time PCR machine (Stratagene). Housekeeping
gene GAPDH was included as an internal endogenous control for ampliﬁcation
efﬁciency and RNA quantiﬁcation.
Cell migration and invasion
HepG2 migration was assessed in a wound healing assay, where a scratch wound
was created in the cell monolayer and cells re-fed with media containing mito-
mycin C (10 lg/ml) in the presence or absence of NSC (1 lM), anti-TGFb or
anti-VEGF (1.5 lg/ml). Cell migration was measured by taking an image of the
scratch from replicate wells at 0 and 24 h post wounding. The wound closure dis-
tance was analyzed with ILab 4.0 software and the difference between 0 and 24 h
calculated.
To assess hepatoma invasion, Huh-7.5 cells were serum starved overnight
and seeded on collagen coated 8 lm transwell permeable membranes (BD, Fal-
con). Cells were allowed to invade for 24 h in the presence or absence of NSC
(1 lM) and non-invading cells removed using a cotton-bud. Invaded cells were
ﬁxed in ice-cold methanol for 5 min, stained with 0.1% crystal violet for 1 h fol-
lowed by washing in PBS and three ﬁelds of view captured using a Nikon
TE200 microscope and the number of invaded cells enumerated.
Statistical analysis
Results are expressed as mean ± 1 standard deviation, unless otherwise stated.
Statistical analyses were performed using the Student t test, (unless otherwise
stated) with a p value of less than 0.05 considered signiﬁcant.Results
HCV glycoproteins modulate tight junction protein localization,
expression and function
To investigate the functional effect(s) of HCV glycoproteins on
tight junction proteins, we utilized the well-characterized human2 vol. 56 j 803–809
40
100
80
60
40
20
0
%
 M
ax
Parental H77 E1E2
Anti-E2 Anti-VSV-G
JFH-1 E1E2 VSV-G
Parental
0 50 100
Receptor expression (MFI)
150
C
la
ud
in
-1
Occludin
Claudin-1
CD81
SR-BI
β-actin
Pa
re
nt
al
H
77
 E
1E
2
JF
H
-1
 E
1E
2
VS
V-
G
Occludin
Claudin-1
CD81
SR-BI
O
cc
lu
di
n
H77 E1E2 JFH-1 E1E2 VSV-G
Parental
H77 E1E2
JFH-1 E1E2
VSV-G
Parental
H77 E1E2
JFH-1 E1E2
VSV-G
***
100
***
A
B
C
D E
JOURNAL OF HEPATOLOGY
HepG2 hepatoblastoma cell line that polarizes in culture [19].
HepG2 cells were transfected to express HCV strains H77 and
JFH-1 glycoproteins or control VSV-G (Fig. 1A). Stable cell popu-
lations were selected for study where the majority of cells
expressed HCV E2 at comparable levels to HCVcc H77/JFH-1
infected hepatoma cells. Tight junction protein expression and
localization in parental and transfected cells was assessed by
confocal microscopy, Western blotting and ﬂow cytometry
(Fig. 1B and C). Occludin localized as discrete bands surrounding
the BC in parental and VSV-G expressing cells, whereas in H77
and JFH-1 E1E2-expressing cells, Occludin localized to the apical
and basolateral membranes and showed reduced expression lev-
els by Western and ﬂow cytometry (Fig. 1B and C). In contrast,
HCV glycoproteins promoted Claudin-1 expression, with no effect
on protein localization (Fig. 1 B and C). There was no discernable
co-localization of HCV E2 with Claudin-1 or Occludin (Supple-
mentary Fig. 1). HCV glycoproteins had no detectable effect on
the expression level of entry factors CD81 and SR-BI (Fig. 1C).
HCV glycoproteins signiﬁcantly reduced HepG2 polarity
(Fig. 1D) and the ability of BC to retain CMFDA (Fig. 1E), demon-
strating an increased permeability. In summary, these data high-
light a role for HCV glycoproteins in perturbing tight junction
protein expression, localization and function that may result in
an abnormal ‘leaky’ hepatic barrier in vivo.
To investigate whether HCV infection perturbs Occludin local-
ization in vivo, formalin-ﬁxed parafﬁn-embedded specimens of
human liver samples from normal, HCV infected, non-alcoholic
steatohepatitis (NASH) and hepatitis B virus (HBV) infected
donors with early and late stage liver disease were stained for
Occludin. In normal tissue, Occludin was only detected at the api-
cal canalicular membrane, whereas basolateral pools were
detected in all inﬂamed liver tissue samples, consistent with a
reduction in apical expression (Fig. 2). The widespread reorgani-
zation of hepatocellular Occludin observed in all samples, inde-
pendent of disease aetiology, suggests an indirect inﬂammatory
response that is not speciﬁc to the HCV infected liver.30
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Fig. 1. HCV glycoproteins perturb tight junction function. (A) Flow cytometric
detection of HCV-E2 and VSV-G, where the ﬁlled histogram depicts an irrelevant
isotype control. (B) Occludin and Claudin-1 (green) localization in parental, HCV
glycoprotein and VSV-G expressing cells, where cell nuclei are counterstained
with DAPI (blue); scale bar represents 20 lm. (C) HCV receptor quantiﬁcation by
Western blot and ﬂow cytometry, where data is presented as mean ﬂuorescent
intensity (MFI) and isotype control value was subtracted. (D) HCV glycoproteins
modulate polarity; cells were grown for 1, 3 and 5 days and their polarity
assessed by enumerating MRP-2 positive BC/100 nuclei in ﬁve independent ﬁelds
of view. (E) HCV glycoproteins reduce tight junction (TJ) integrity; cells were
allowed to polarize for 5 days and tight junction integrity quantiﬁed by
determining the number of BC retaining CMFDA. ⁄⁄⁄p <0.001.Mechanism(s) underlying HCV glycoprotein modulation of tight
junction function
Altered tight junction protein location is frequently linked with
an invasive tumor phenotype and we therefore studied the effect
of viral glycoproteins on HepG2 migration and invasion. HepG2
cells expressing HCV glycoproteins demonstrated a signiﬁcantly
increased migratory capacity compared to parental or VSV-G
expressing cells (Fig. 3A). Consistent with this increased migra-
tory capacity of HCV glycoprotein containing cells, expression
of the cell adhesion molecule, E-Cadherin, was reduced
(Fig. 3B). To ascertain whether HCV glycoproteins promote a
de-differentiation process reminiscent of EMT, we investigated
expression of EMT-associated transcription factors, Snail and
Twist. HCV glycoproteins promoted Snail and Twist expression
(Fig. 3B). Since these transcription factors are regulated by HIF-
1a; a transcription factor associated with the expression of genes
involved in tumor invasion, we studied the effect(s) of HCV gly-
coproteins on HIF-1a expression. Both HCV glycoprotein strains
promoted HIF-1a expression under normoxic conditions
(Fig. 3C). Treating cells with HIF-1a inhibitor NSC reduced HIF-
1a expression (Supplementary Fig. 2) and restored the migratory
capacity and tight junction integrity of HCV glycoprotein express-
ing cells to levels observed with parental and VSV-G expressingJournal of Hepatology 201cells (Fig. 3D). Treating HepG2 cells with desferrioxamine, an iron
chelator that stabilizes HIF-1a, increased hepatoma migration2 vol. 56 j 803–809 805
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Fig. 2. Occludin localization in normal and diseased liver tissue. (A) Repre-
sentative immunohistochemical stain of Occludin in the normal, early and late
stage HCV infected liver (200), where the arrow shows Occludin at bile
canalicular (BC) or basolateral (BM) hepatocyte membranes. (B) Occludin
distribution in ﬁve cases of normal, HCV infected, NASH inﬂamed or HBV
infected tissue was graded as follows: 0 = <5%; 1 = 5–33%; 2 = 33–66% and
3 = >66%. The basolateral distribution in all inﬂamed tissue was signiﬁcantly
higher compared to normal tissue.
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Fig. 3. HCV glycoproteins promote hepatoma migration. (A) Increased migra-
tion of HCV glycoprotein expressing HepG2 cells; where migration was deter-
mined over a 24 h period in a scratch-wound assay. Data is presented as
percentage migration. (B) Expression of E-Cadherin and EMT markers Snail and
Twist. (C) HCV glycoproteins and VSV-G stabilize HIF-1a: nuclear HIF-1a was
visualized by confocal microscopy; scale bar represents 20 lm. (D) The effect of
HIF-1a inhibitor NSC (1 lM) on HepG2 migration and tight junction integrity.
Cells were treated with NSC for 24 h and the difference in migration and tight
junction integrity determined. (E) HIF-1a staining in normal and HCV infected
liver tissue, where the arrow indicates nuclear expression. ⁄⁄p <0.01, ⁄⁄⁄p <0.001.
Research Articlethreefold, demonstrating a role for HIF-1a in hepatomamigration
independent of HCV infection. Importantly, we observed hepato-
cellular HIF-1a expression in chronic HCV infected liver tissue
(Fig. 3E), demonstrating a focal nuclear staining pattern that
was absent in normal liver samples. In summary, HCV glycopro-
teins increase HepG2 migration and promote the expression of
EMT transcription factors Snail and Twist via a HIF-1a driven
pathway.
HCV infection promotes hepatoma migration in a HIF-1a dependent
manner
To validate these observations with the infectious virus, we
assessed the effect(s) of HCVcc strain J6/JFH-1 infection on hepa-
toma migration using two model systems: a scratch wound assay
that measures cell migration within the context of a monolayer
and a collagen invasion assay that quantiﬁes hepatoma migration
through an extracellular matrix. HCVcc infection signiﬁcantly
increased HepG2-CD81 and Huh-7.5 migration (Fig. 4A and B)
and promoted Snail and Twist expression in both hepatoma cell
lines and primary human hepatocytes (Fig. 4C). Furthermore,
HIF-1a inhibitor NSC restored the migratory capacity of infected
hepatoma cells to parental levels and ablated Snail and Twist
expression (Fig. 4A–C), conﬁrming a HIF-1a dependent process.
We previously reported on the low permissivity of HepG2 cells
to support HCV replication [19], raising questions as to how a
small number of infected cells affect the migration of the cell
population under study. To address this question, the highly per-
missive Huh-7.5 hepatoma cell line was infected with a low level
of infectious virus to generate distinct populations of infected and
uninfected cells. HIF-1a was only detected in NS5A antigen
expressing cells in the infected culture (Fig. 4D), consistent with
the focal HIF-1a staining observed in HCV infected liver tissue806 Journal of Hepatology 201(Supplementary Fig. 3). In contrast, the majority of cells in the
infected population expressed Snail and Twist, independent of
viral antigen expression, suggesting a bystander effect (Fig. 4D).
Recent studies have shown that HCV infection stabilizes HIF-
1a expression via an ER-stress response that activates PI3K,
MAPK and NFKB pathways, leading to increased VEGF and TGFb
expression [22–25]. To ascertain whether HCV glycoproteins pro-
mote VEGF and TGFb expression, parental and glycoprotein
expressing cells were analyzed for cytokine expression. There
was a signiﬁcant increase in both VEGF and TGFb expression in
HCV glycoprotein expressing cells (Supplementary Fig. 4A). Neu-
tralizing antibodies targeting VEGF or TGFb partially restored
tight junction integrity in HCV glycoprotein expressing cells,
where neutralizing both cytokines resulted in a phenotype indis-
tinguishable from the parental cells (Supplementary Fig. 4B).2 vol. 56 j 803–809
Snail
Twist
β-actin
Snail
Twist
β-actin
20
15
10
5
0
H
ep
G
2-
C
D
81
m
ig
ra
tio
n 
(%
)
HepG2-
CD81
A B
C
D
Control
Mock HCV
M
oc
k
H
C
V
M
oc
k
H
C
V
M
oc
k
H
C
V
C
on
tro
l
N
SC
C
on
tro
l
N
SC
C
on
tro
l
N
SC
NSC Control NSC
*** ***
250
200
150
100
50
0
R
el
at
iv
e 
in
fe
ct
io
n
HepG2-
CD81
E F
N
or
m
ox
ia
H
yp
ox
ia
N
or
m
ox
ia
H
yp
ox
ia
150
100
50
0
R
el
at
iv
e 
in
fe
ct
io
n
C
on
tro
l
N
SC
C
on
tro
l
N
SC
104
103
102
101
100H
C
V 
co
pi
es
/G
AP
D
H
C
on
tro
l
N
SC
C
on
tro
l
N
SC
200
150
100
50
0H
uh
-7
.5
 in
va
si
on
 (%
)
Huh-7.5
Huh-7.5
PHH
HepG2-
CD81 Huh-7.5 PHH
Control
Mock HCV
NSC Control NSC
*** ***
Snail
NS5A
Nucleus
HIF-1α
NS5A
Nucleus
Twist
NS5A
Nucleus
HepG2-
CD81
Huh-7.5 PHHHuh-7.5
**
****
*
Fig. 4. HCV infection promotes hepatoma migration in a HIF-1a dependent
manner. HepG2-CD81 (A) and Huh-7.5 (B) cells were infected with HCVcc J6/JFH-
1 and their migratory capacity after 48 h assessed in a scratch wound assay and
collagen invasion assay respectively, in the presence or absence of NSC (1 lM).
Data is presented relative to control untreated cells. The number of NS5A
expressing HepG2-CD81 and Huh-7.5 cells per well was 1.7  103 and 9  104,
respectively. (C) Snail and Twist expression in mock and HCV infected hepatoma
and primary human hepatocytes (PHHs), where NSC treatment ablated Snail and
Twist expression. Infected PHHs and Huh-7.5 cells contained 4.1  105 HCV RNA
copies/105 cells and 3.2  107 HCV RNA copies/105 cells, respectively. (D) Huh-7.5
cells were infected with HCV J6/JFH-1 at low multiplicity of infection (0.01) for
48 h and co-stained for NS5A (red), HIF-1a, Snail and Twist (green), and nuclei
counterstained with DAPI (gray); scale bar represents 20 lm. (E) The effect of
hypoxia (1% O2) on HCV infection of hepatoma cells; cells were infected under
hypoxic or normoxic conditions and infection determined 48 h later by enumer-
ating NS5A expressing cells, data is presented relative to normoxic conditions.
Treating infected cells with HIF-1a inhibitor NSC (1 lM) reduced viral infection;
data is presented relative to untreated cells. (F) HCV replication in Huh-7.5 cells
and PHHs in the presence or absence of HIF-1a inhibitor NSC (1 lM). Data is
presented as HCV copy numbers relative to GAPDH. ⁄p <0.05, ⁄⁄p <0.01,
⁄⁄⁄p <0.001.
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Journal of Hepatology 201Importantly, neutralizing TGFb reduced the migration of HCV gly-
coprotein expressing cells to levels seen with parental and VSV-G
expressing cells (Supplementary Fig. 4C). In contrast, neutralizing
VEGF had no detectable effect on hepatoma migration (Supple-
mentary Fig. 4C), consistent with experiments showing that
exogenous TGFb promotes HepG2 migration whereas VEGF had
no effect. We conﬁrmed that HCV infection promotes VEGF and
TGFb expression [22–25] and NSC treatment ablated growth fac-
tor expression (Supplementary Fig. 5A). Furthermore, neutraliz-
ing TGFb ablated Snail and Twist expression in both NS5A
expressing and non-expressing cells in the infected population
(Supplementary Fig. 5B), conﬁrming a role for TGFb in EMT tran-
scription factor expression.
Since low oxygen or hypoxia is known to stabilize HIF-1a, we
investigated the effects of hypoxia on HCV replication. Hypoxia
signiﬁcantly increased HCVcc infection of Huh-7.5 and HepG2-
CD81 cells and treating cultures with NSC reduced viral infection
and had no effect on HCV pseudoparticle entry (Fig. 4E, data not
shown). We conﬁrmed these observations with primary human
hepatocytes where NSC signiﬁcantly reduced HCV RNA levels
(Fig. 4F), demonstrating a positive role for this transcription fac-
tor in the HCV lifecycle. Treating hepatoma cells with an indepen-
dent HIF-1a inhibitor, RITA, conﬁrmed these ﬁndings (data not
shown). Taken together, these data provide a new paradigm for
HCV to modulate HIF-1a dependent pathways that promote
HCC growth and HCV replication.Discussion
Our studies show that HCV infection and the viral encoded glyco-
proteins reduce hepatoma polarity and increase cell migration by
stabilizing HIF-1a expression and upregulating downstream
effectors, VEGF and TGFb. Neutralization of both growth factors,
or inhibition of HIF-1a, restored the polarity and migratory
capacity of infected cells. Furthermore, inhibiting HIF-1a signiﬁ-
cantly reduced HCV replication in hepatoma cell lines and pri-
mary hepatocytes, highlighting a dual role for this transcription
factor in the viral life cycle and hepatoma migration.
HIF-1a expression has been reported to associate with EMT, a
reversible developmental process where epithelial cells reduce
intercellular adhesion and acquire ﬁbroblastoid properties that
promote an invasive and metastatic phenotype [12,26]. EMT
plays a major role in the invasive and metastatic potential of
human cancers [27,28]. EMT transcription factors Snail and Twist
are expressed in 40–70% of HCCs and associate with adherens
junction disruption and poor prognosis [29,30]. Similarly, ectopic
expression of Snail or Twist in hepatoma cell lines enhances their
motility and invasiveness [30,31]. Yang and co-authors reported
that increased Twist expression was more frequently observed
in HCC associated with HCV infection than with other liver dis-
eases [30]. The poor prognosis of HCC is largely due to the inva-
sive nature of the tumor, with frequent intrahepatic and
extrahepatic metastases [3]. Therapeutic options for patients
with HCC are limited. Curative approaches, including surgical
resection and liver transplantation are attempted in approxi-
mately 30% of patients, however, cancer recurrence following
surgery is in the order of 60–70% within 5 years [32]. This study
provides a potential explanation for the clinical observation that
HCV associated HCC is frequently more aggressive [7] and high-
lights a mechanism for HCV to accelerate the malignant process.2 vol. 56 j 803–809 807
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Recent reports demonstrate that HCV promotes TGFb expres-
sion and activates p38MAPK, JNK, ERK and NFjB pathways
[23,24]. TGFb promotes EMT and plays a major role in the dis-
semination of malignant hepatocytes during HCC progression
[33,34]. Our data showing a role for TGFb in the increased migra-
tory capacity of HCV infected hepatoma cells, supports a role for
HCV in promoting tumor spread rather than a direct role in the
oncogenic process per se. We failed to observe any morphological
ﬁbroblast features of infected or HCV glycoprotein expressing
hepatoma cells, suggesting a partial de-differentiation process
in vitro. Mazzocca et al. recently reported that inhibition of TGFb
receptor I kinase blocked HCC growth, supporting a rationale for
therapeutic targeting of TGFb signaling in HCV associated HCC
[35].
Our observation that VEGF and TGFb perturb tight junction
protein localization and function supports our in vivo observa-
tions demonstrating a widespread reorganization of Occludin in
the diseased human liver. Benedicto and colleagues reported that
HCV glycoproteins associate with Occludin and alter protein traf-
ﬁcking in Huh-7 cells [36]. In contrast, we failed to immunopre-
cipitate Occludin and HCV glycoproteins in a variety of cell lines
transduced to express HCV E1E2 or in HCV infected cells (data not
shown). Furthermore, VEGF or TGFb had no detectable effect on
the expression or localization of Occludin or other tight junction
proteins in Huh-7 cells, suggesting that these cells are refractory
to these cytokines [10].
HCV infection is one of the leading indications for liver
transplantation and the number of patients requiring trans-
plantation for chronic hepatitis C is increasing. HCV infects
the newly transplanted liver in all cases, leading to a more rap-
idly progressive disease and frequent graft loss [37]. Recurrent
HCV is recognized as one of the major challenges facing liver
transplantation in the next decade [38]. Currently available
antiviral treatments are poorly tolerated and have limited efﬁ-
cacy in patients after transplant and new therapies are urgently
required. Injury to the liver at the time of transplantation (i.e.
ischaemia reperfusion injury, IRI) has been associated with
more aggressive recurrent HCV disease [39], however, the fac-
tors governing viral replication rate(s) in the newly trans-
planted liver are poorly understood. Our demonstration that
hypoxia, a key event during hepatic IRI, increases virus replica-
tion provides a potential explanation for these clinical observa-
tions and highlights the potential value of short term anti-
oxidant or HIF-1a inhibitor treatment at the time of transplan-
tation to limit HCV replication.
In summary, we have shown a central role for HIF-1a in stim-
ulating VEGF and TGFb that alters hepatocyte behavior and pro-
motes malignancy in the HCV infected microenvironment. We
have also demonstrated a role for HIF-1a in HCV infection. These
ﬁndings highlight a potential role for HIF-1a inhibitors as thera-
peutics in patients with both HCC and HCV infection.Authors’ contributions
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